US OptionsDetailed Quotes
RIGL240920C5000
- 0.05
- 0.000.00%
15min DelayClose Apr 1 10:39 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-63.27%PremiumSep 20, 2024Expiry Date8.75Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.61Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Rigel Pharmaceuticals Stock Discussion
C'mon 14.+
Rigel to Present at the 2024 Cantor Global Healthcare Conference
just
Rigel Announces First Patient Enrolled in Phase 1B/2 Triplet Therapy Trial of Rezlidhia® (Olutasidenib) in Midh1 Aml
On September 3, 2024, Rigel Pharmaceuticals, Inc. (“Rigel”) entered into a collaboration and license agreement (the “License Agreement”) and a supply agreement (the “Supply Agreement”) with Kissei Pharmaceutical Co., Ltd. (“Kissei”). Pursuant to the terms of the License Agreement, Kissei received exclusive rights to develop and commercialize olutasidenib in all human diseases in Japan, the R...
13.88
Bring on 14.+
No comment yet